Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Nicox SA is currently managing 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 3 pending office actions are assigned to 3 distinct examiners, but the work is distributed across only 2 distinct art units. MICAH PAUL YOUNG is the busiest examiner with 1 busiest examiner pending office action. This workload is shared equally with the other 2 examiners involved in the portfolio.
The presence of 3 distinct examiners for 3 pending office actions means there is no examiner overlap in the current portfolio. However, the 2 distinct art units indicate that at least two examiners are operating within the same administrative group. This requires the applicant to navigate 3 different examiner styles while adhering to the technical standards of 2 distinct art units. The Biotechnology & Pharmaceuticals technology area provides the overarching context for all 3 pending office actions. Practitioners should note that the busiest examiner, MICAH PAUL YOUNG, only handles 1 busiest examiner pending office action, matching the workload of the other examiners. This distribution requires a strategy that addresses the unique perspectives of 3 distinct examiners across the 2 art units involved.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| TOWNSLEY, SARA ELIZABETH | 1 | 25.6% | +48.2% |
| NEAGU, IRINA | 1 | 46.7% | +57.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18841347 | METHOD FOR THE TREATMENT OF ANTERIOR ISCHEMIC OPTIC NEUROPATHY | TOWNSLEY, SARA ELIZABETH | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18841347 | METHOD FOR THE TREATMENT OF ANTERIOR ISCHEMIC OPTIC NEUROPATHY | TOWNSLEY, SARA ELIZABETH | — |
| 18714300 | OPHTHALMIC PHARMACEUTICAL COMPOSITIONS CONTAINING A NITRIC OXIDE-RELEASING PHOSPHODIESTERASE 5 INHIBITOR AND METHOD FOR THE PREPARATION THEREOF | NEAGU, IRINA | — |
| Art Unit | Apps |
|---|---|
| 1629 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18841347 | METHOD FOR THE TREATMENT OF ANTERIOR ISCHEMIC OPTIC NEUROPATHY | TOWNSLEY, SARA ELIZABETH | 1629 | §101§102§112DP | Non-Final OA | — | Pending | Aug 23, 2024 |
| 18714300 | OPHTHALMIC PHARMACEUTICAL COMPOSITIONS CONTAINING A NITRIC OXIDE-RELEASING PHOSPHODIESTERASE 5 INHIBITOR AND METHOD FOR THE PREPARATION THEREOF | NEAGU, IRINA | 1629 | §103§112DP | Non-Final OA | — | Pending | May 29, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNicox SA has 2 pending office actions as of October 2026, spread across 1 art units and 2 examiners.
Sara Elizabeth Townsley has the most, with 1 of Nicox SA's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
